Right to Try Clarification Act
United States118th CongressHR-1825House of Representatives
Updated: Apr 7, 2023
Summary
Right to Try Clarification Act This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances). The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.
Bill texts
All available records shown.
Timeline
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
House of Representatives
Introduced in House
Sponsor introductory remarks on measure. (CR E267)
Referred to the Subcommittee on Health.
House of Representatives
All available records shown.